Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06427941 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06427941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06427941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
Lead sponsor
BeOne Medicines
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 23, 2024
Completion date
October 31, 2028
Enrollment
630 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-fetoprotein (afp)-producing gastric cancer, extragonadal yolk sac tumors, glypican-3 (gpc3)-positive squamous non-small cell lung cancer, local advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma